STEERLife announces its solvent-free melt fusion technology
STEERLife has initiated the development of several drug products including generic versions of ERLEADA (Apalutamide), XTANDI (Enzalutamide), VENCLEXTA (Venetoclax), and LYNPARZA (Olaparib)
STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. At the core of this advancement is STEERLife’s solvent-free melt fusion technology, a continuous processing system that eliminates the need for harmful organic solvents. Designed to handle high-potency and hard-to-develop molecules, this platform significantly enhances formulation efficiency, safety, and scalability.
STEERLife provides comprehensive development capabilities for complex and potent drugs – including NCEs, hormone therapies, orphan drugs, complex generics (ANDAs) and 505(b)(2) products, assisting global pharma in overcoming development and manufacturing challenges through process-driven innovation.
“Potent drug development demands more than just compliance; it requires control, care, and innovation,” said Indu Bhushan, CEO & Director, STEERLife. “Our continuous, solvent-free platform brings all of that together – enabling faster, cleaner and more scalable development for the world’s most demanding therapies.”
STEERLife has already initiated the development of several key drug products set for market release from 2026 onwards. These include generic versions of ERLEADA (Apalutamide), XTANDI (Enzalutamide), VENCLEXTA (Venetoclax), and LYNPARZA (Olaparib).
Working in tandem with partner facilities, STEERLife aims to serve leading pharmaceutical markets across the United States, Europe, Latin America, Russia, MENA and Southeast Asia.